Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

InnoCan Pharma Corporation (INNO.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.8000-0.0400 (-4.76%)
At close: 3:59PM EDT
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8400
Open0.8300
Bid0.7900 x N/A
Ask0.8400 x N/A
Day's Range0.8000 - 0.8300
52 Week Range0.2000 - 1.6500
Volume89,563
Avg. Volume426,643
Market Cap177.162M
Beta (5Y Monthly)4.55
PE Ratio (TTM)N/A
EPS (TTM)-0.0870
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for INNO.CN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Newsfile

      Innocan Reports of Presence of CBD in Mice's Brains 41 Days After Injection of CBD Using Innocan's Liposome Platform Technology

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 19, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to announce the results of a recent study showed the presence of Cannabidiol (CBD) in mice's brains, 41 days after being injected with Innocan's CBD LPT (CBD-Loaded Liposome Platform Technology). In contrast, no CBD was demonstrated in mice's brains, 22 days following the injection of free CBD (without ...

    • Newsfile

      Innocan Pharma Corporation Closes C$8.2 Million Private Placement with Institutional Investors

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 13, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has closed its previously announced private placement of the Company's common shares (a "Common Share" and, collectively, the "Common Shares") and warrants to purchase common shares ("Common Warrants") to institutional investors for aggregate gross proceeds to the Company of C$8,227,150 million (the "Pr

    • Newsfile

      Innocan Pharma Corporation Announces C$8.2 Million Private Placement with Institutional Investors

      Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - October 8, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), today announced that it has entered into securities purchase agreements for a private placement of the Company's common shares (a "Common Share" and, collectively, the "Common Shares") and warrants to purchase common shares ("Common Warrants") to institutional investors for aggregate gross proceeds to the Company of approximate

    Advertisement
    Advertisement